Human effector memory (EM) CD4 T cells may be recruited from the blood into a site of inflammation in response either to inflammatory chemokines displayed on or specific Ag presented by venular endothelial cells (ECs), designated as chemokine-driven or TCR-driven transendothelial migration (TEM), respectively. We have previously described differences in the morphological appearance of transmigrating T cells as well as in the molecules that mediate T cell-EC interactions distinguishing these two pathways. In this study, we report that TCR-driven TEM requires ZAP-70-dependent activation of a pathway involving Vav, Rac, and myosin IIA. Chemokine-driven TEM also uses ZAP-70, albeit in a quantitatively and spatially different manner of activation, and is independent of Vav, Rac, and mysosin IIA, depending instead on an as-yet unidentified GTP exchange factor that activates Cdc42. The differential use of small Rho family GTPases to activate the cytoskeleton is consistent with the morphological differences observed in T cells that undergo TEM in response to these distinct recruitment signals.
A critical step in the inflammatory response is the recruitment of circulating leukocytes across activated postcapillary venular endothelium into the peripheral tissues. The multistep paradigm of myeloid leukocyte recruitment starts with sequential tethering, rolling, firm attachment, and intraluminal crawling on the endothelial cell (EC) surface until the leukocyte is positioned above or near an interendothelial cell junction. The process concludes with cytoplasmic probing and cell process penetration of and ultimately transmigration across the endothelial monolayer (1) . Activated venular ECs express leukocyte adhesion molecules that mediate tethering, rolling, and firm adhesion and display chemokines that interact with chemokine receptors on the rolling leukocytes. Leukocyte responses to chemokines mediate all but the initial tethering and rolling steps in this cascade so that recruitment may be said to be chemokine-driven. T cells in the circulation may be divided into various subsets including naive and central memory T cells that recirculate to secondary lymphoid organs and effector memory (EM) T cells (identified as CCR7 2 , CD62L 2 , CD45RA 2 , and CD45RO + ) that can be recruited to peripheral sites of inflammation (2, 3) . EM T cells may follow the same general paradigm as myeloid leukocytes and will transmigrate in response to chemokines bound to luminal proteoglycans on the EC surface (4) . In the presence of shear stress comparable to that present in postcapillary venules, EM CD4 T cells can complete the process of transendothelial migration (TEM) across a microvascular EC monolayer in vitro within 10-15 min. The requirement for shear stress as an inducer of rapid TEM is unique to T cells (5) . Primary resting human T cells crawling on the EC in the presence of shear stress are polarized, displaying a leading edge and a trailing uropod. Shear stress has been proposed to allow mechanical stretching of T cell LFA-1 molecules attached to EC ICAM-1, leading to a greater increase in LFA-1 affinity than that produced by chemokine signaling alone (6) . As the T cell approaches an interendothelial junction, it extends submicron ventral adhesive and invasive filipodia into the EC surface and subsequently into the junction between ECs, creating a gap through which TEM occurs (7) .
EM T cells may alternatively undergo TEM by a process that is independent of chemokines. Human venular ECs in peripheral tissues basally express both MHC class I and class II molecules, enabling them to present Ags and thus signal through the TCR of a rolling EM CD8 or CD4 T cell, respectively. Because TCRs are clonally expressed, very few T cells actually respond to any particular Ag. In vivo, this is not a problem because the circulatory system constantly delivers fresh EM T cells to sample the Ags displayed by the venular ECs and those rare EM T cells that recognize their cognate Ag may serve as "pioneer cells," initiating a recall response (8) . Experimentally, the number of T cells capable of being activated through their TCR can be increased (and thus studied in vitro) by presentation of a superantigen, such as toxic shock syndrome toxin 1 (TSST-1), that can be recognized by 5-20% of peripheral blood EM T cells. Surprisingly, the activation of TCR signaling in EM CD4 T cells blocks TEM in response to inflammatory chemokines (9) . Instead, TCR-activated EM CD4 T cells round up on the EC surface and extrude a long (up to 20 mm) cytoplasmic protrusion that crosses and tunnels beneath the EC monolayer; we have designated these structures as transendothelial protrusions (TEPs). In experiments using microvascular ECs, the T cell body eventually follows the TEP in a second step that depends on EC expression of fractalkine (10) . In addition to the morphological differences from chemokine-driven TEM, TCR-driven TEM is slower (requiring ∼50 min) but similarly requires shear stress and uses LFA-1. However, TCR-driven TEM involves several EC junctional molecules, such as platelet-endothelial cell adhesion molecule-1 (CD31), CD99, and polio virus receptor (CD155) or nectin-2 (CD112), engaged by their cognate receptors on the T cell that are not required for chemokine-driven TEM (10) (11) (12) .
Because changes in cell shape, exemplified by TEP formation, are generally controlled by changes in the actin cytoskeleton and because TEP formation is only observed in TCR-driven TEM, we reasoned that the cytoskeleton of EM CD4 T cells must undergo different forms of reorganization following TCR versus chemokine signaling. Some of the pathways by which TCR or chemokine receptors can modulate the cytoskeleton are well described (13, 14) . An early step in TCR signaling involves phosphorylation of tyrosine residues of several ITAMs located within the cytoplasmic portions of the TCR-associated CD3 protein subunits, including the z-chains, by src family kinases such as lck or fyn. These phosphorylated ITAMs then serve as binding sites for ZAP-70, a syk family cytosolic tyrosine kinase, that is, in turn, activated through phosphorylation by src family kinases. Activated ZAP-70 then phosphorylates TCR-associated adaptor proteins such as LAT and SLP76, forming a complex that serves as a scaffold for the recruitment and activation of Vav, a GTP exchange factor (GEF) that activates Rac, a small Rho family GTP-binding (G) protein.
Among other actions, Rac can reorganize the actin cytoskeleton in a manner that leads to polarized outgrowths of cell protrusions such as lamellipodia (15) . Chemokine receptors are G proteincoupled receptors that serve as GEFs for trimeric G protein family members, and chemokine binding results in trimeric G protein activation. Through processes that are less well understood, activated trimeric G proteins may activate both cytosolic tyrosine kinases (such as ZAP-70 in T cells) and small Rho family G proteins such as Rho, Rac, and/or Cdc42. Rho and Cdc42, like Rac, can reorganize the actin cytoskelton, but Rho typically mediates cellular retraction and Cdc42 commonly promotes the formation of filopodia (15) . Thus, on the basis of morphological difference between TCR-driven TEM (such as TEP formation) and chemokine-driven TEM (such as filopodia formation), it seemed likely that TCR and chemokine signaling would result in distinct patterns of small G protein activation. In addition to causing cell shape change, rearrangements of the actin cytoskeleton also modulates T cell attachment to other cells by regulating integrin affinity. The principal integrin expressed by T cells that mediates attachment to endothelial cells is LFA-1 (CD11a/CD18), and the control of LFA-1 affinity for its ligands on the endothelium is mediated through proteins that link actin filaments to the intracellular tails of the LFA-1 b-chain, namely talin and kindlin 3, the latter being associated with the scaffold protein RACK1 (16, 17) . Binding of these linker proteins to the intracellular domains of the integrin b-chain causes the extracellular domains of both the LFA-1 a-and b-chains to extend and bind more tightly to ICAM-1. The quantity and distribution of extended forms of LFA-1 as well as the linker proteins associated with the cytoplasmic tail of LFA-1 may well change in a different manner in response to TCR versus chemokine signaling.
In the current study, we have used a variety of approaches to analyze signaling events of the distinct processes of TEM that we have observed with a focus on small G proteins and the cytoskeleton. By means of pharmacological inhibition, we show that ZAP-70 activation is necessary for TCR-driven TEP formation and TEM as well as for chemokine-driven TEM. However, as detected by immunofluorescence microscopy, these stimuli activate ZAP-70 and LAT in a quantitatively and spatially distinct manner. Similarly, the cellular distribution of activated LFA-1, talin, and RACK1 reflect the morphological changes attendant with TCR-driven TEM. By transducing primary EM CD4 T cells with membrane-permeable recombinant proteins, we show that Vav and its target small G protein Rac are required for TCR-driven TEM, whereas the small G protein Cdc42 controls chemokine-driven TEM in a manner that is independent of Vav and Rac. Furthermore, pharmacological inhibition suggests that myosin IIA is necessary for TCR-driven TEM but dispensable for TEP formation and for chemokine-driven TEM. These differences in the manner by which TCR versus chemokine receptors affect the cytoskeleton further highlight differences between these two modes of T cell recruitment to sites of inflammation.
Materials and Methods

Cells and reagents
All human materials were obtained from de-identified blood or tissue donors under protocols approved by the Yale Human Investigation Committee. CIITA-transduced human dermal microvascular EC (HDMEC) were generated using a retroviral vector and characterized as described previously (10) . Prior to flow experiments, CIITA HDMEC were incubated in the presence of 10 ng/ml recombinant human TNF-a (R&D Systems) for 18-28 h to upregulate adhesion molecules and inflammatory chemokines and then overlaid with 100 ng/ml recombinant TSST-1 (Toxin Technology) for 30 min to allow TCR-mediated activation of all T cells that use a Vb2 gene segment to form their TCR, ∼5-20% of the circulating T cells in most donors.
Leukapheresis was performed on healthy adult donors, and PBMCs were enriched by Ficoll-Hypaque density gradient centrifugation prior to cryopreservation of aliquots. Total peripheral blood CD4 T cells were isolated from the cryopreserved samples by positive selection with CD4 Dynabeads magnetic beads and released with Detachabead (Dynal Biotech). Memory (CD4 + CD45RA
2 ) T cells were enriched by depletion of CD45RA cells from CD4 T cells using anti-CD45RA mAb (eBioscience) and pan-mouse IgG beads (Dynal Biotech). EM CD4 T cells were further purified from the total CD4 memory pool by depletion of central memory markers with anti-CCR7 mAb (R&D Systems) and anti-CD62L (eBioscience) and pan-mouse IgG beads. Approximately 90% of the initial T cell population as well as essentially all other leukocyte types were removed by these manipulations. The remaining 10% of CD4 T cells, highly enriched for EM CD4 T cells, was cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine, and penicillin/streptomycin (all from Invitrogen) overnight prior to assays. In experiments in which we used transduction of dominant-negative (DN) proteins, the EM CD4 T cells were transduced with recombinant proteins for 2 h and then washed prior to the overnight incubation. Where indicated, EM CD4 T cells were treated with piceatannol (Calbiochem) and Syk inhibitor II (Calbiochem) to inhibit ZAP-70, with blebbistatin (Sigma-Aldrich) to inhibit myosin IIA, ML-7 (Calbiochem) to inhibit myosin L chain kinase, EHop-016 (Calbiochem) to inhibit Rac, and Cdc42,6-Thio-GTP (Jena Bioscience) to inhibit Vav or vehicle control (DMSO) and then washed prior to flow TEM assays.
Abs used to stain the samples are as follows: anti-Vb2TCR mAb (Meridian Life Science), anti-NFAT mAb (BD Biosciences), anti-phospho-ZAP-70 (Tyr 319 ) rabbit polyclonal Ab (Cell Signaling Technology), anti-CD18 mAb, clone MEM-148 (Enzo Life Sciences), anti-P-LAT (Tyr 191 ) rabbit polyclonal Ab (Cell Signaling Technology), anti-talin mAb clone 8d4 (Sigma-Aldrich), anti-RACK1 mAb (Santa Cruz Biotechnology). Phalloidin-488 (Invitrogen) was used to stain F-actin, and DAPI in the mounting media (ProLong Gold; Invitrogen) to stain nuclei.
Preparation of cell-permeable recombinant proteins
Bacterial expression constructs encoding His-tagged Hph1-enhanced GFP (EGFP)-Rac1 and Hph-1-EGFP-Cdc42 wild-type (wt) and DN proteins were made by subcloning the products of PCR using EGFP-Rac1 and EGFP-Cdc42 plasmids (Addgene plasmids 12980, 12982, 12599, and12601 corresponding to Rac1 wt, Rac1 DN, Cdc42 wt, and Cdc42 DN, respectively, provided by G. Bokoch [Scripps Research Institute, La Jolla, CA] (18) and K. Hahn [University of North Carolina School of Medicine, Chapel Hill, North Carolina] (19)) as templates with 59-GGATCCGTATGCGCGCGT GCGCCGTCGCGGCCCGCGTCGCGGTGGTGGTATGGTGAGCAAGGG CGAGGAGCTG-39 and 59-TAGAAGGCACAGTCGAAGG-39 as primers into the BamHI and XhoI sites of pET28b (Novagen); PCR products were cloned into pCR 2.1-TOPO vector (Invitrogen) and sequenced prior to subcloning into pET-28b. Similarly, His-tagged Hph1-EGFP and Hph-1-EGFP-Vav DN were made using pEGFP-c1 (BD Clontech) and pNM117 [a plasmid provided by X. Bustelo (University of Salamanca, Salamanca, Spain) that encodes EGFP-Vav SH3-SH2-SH3 (20)] as templates. However, because of the presence of a BamHI site in the 39-untranslated region of the Vav1 cDNA in pNM117, the Vav DN construct was subcloned into the BamHI site only of pET-28b. Recombinant proteins were purified from BL21 (DE3) bacteria containing pET-28b constructs induced with 1 mM isopropyl b-D-thiogalactoside for 5-6 h at 30˚C using Talon metal affinity resin as described by the manufacturer (BD Clontech) using imidazole for elution from the resin and then concentrated with Amicon centrifugal filters.
FACS analysis
Flow cytometry standard files of EM CD4 T cells transduced (or not) with GFP fusion recombinant proteins were acquired using an LSRII flow cytometer (BD Biosciences) with FACSDiva software (BD Biosciences) and analyzed using FlowJo software (Tree Star).
TEM assays
CIITA HDMEC were grown to confluence on 20 mg/ml human plasma fibronectin-coated 35-mm coverglasses, treated with TNF and loaded with TSST-1 as previously described, washed twice with RPMI 1640 medium/ 10% FBS, and a parallel plate flow chamber apparatus (Glycotech) using the 0.01-inch-high, 5-mm-wide slit gasket provided by the manufacturer was mounted on the coverglass. On a 37˚C heating surface, CD4 + CD45RA
2 CCR7 low CD62L low (EM) human T cells (10 6 cells/500 ml) suspended in the same medium were loaded onto the EC monolayer at 0.75 dyne/cm 2 for 2 min, followed by washing with medium only at 1 dyne/cm 2 for 5, 15, 30, or 50 min. Samples were then fixed with 3.7% formaldehyde in PBS, stained with anti-Vb2TCR mAb, followed by Alexa Fluor 546-, 568-, or 488-conjugated donkey or goat anti-mouse IgG, mounted on slides using mounting medium containing DAPI (Prolong Gold; Invitrogen), and examined by microscopy with a Zeiss Axiovert 200M microscope. An FITC filter was used to detect FITC or Alexa Fluor 488-stained cells, a tetramethylrhodamine isothiocyanate filter was used to detect PE and Alexa Fluor 546-and 568-stained cells, a DAPI filter was used to detect DAPI-stained nuclei, and a Cy5 filter was used to detect Alexa Fluor 647-stained cells. A 340/0.60 korr Ph2 objective and phase contrast optics were used to determine whether CD4 T cells were either on top or underneath the HDMEC monolayer. T cells that were captured on top of the monolayer but not spread were round and bright when viewed under phase contrast. CD4 T cells that were spread but still on top of the HDMEC monolayer were surrounded by a bright corona of light in contrast to those that had transmigrated, which were dark without a corona of light. The percentage of transmigrated CD4 T cells was calculated for 100-200 cells/ sample by analyzing 5-10 groups of 20 cells each, calculating the percentage for each group and calculating the mean and SEM for the groups. For NFAT staining, anti-NFAT mAb was precomplexed with Zenon-647 (Invitrogen) and incubated with Triton X-100-permeabilized samples after anti-Vb2TCR mAb and anti-mouse IgG staining. Activated ZAP-70 and p-LAT were detected by using anti-Vb2TCR mAb and anti-phospho (Tyr   319 )-ZAP-70 and anti-phospho (Tyr 191 )-LAT rabbit polyclonal Abs, followed by Alexa Fluor 488-or 546-conjugated donkey anti-mouse IgG and Alexa Fluor 647-conjugated chicken anti-rabbit IgG (Invitrogen), and mounted on slides using mounting medium containing DAPI. Staining was quantified with ImageJ.
Confocal microscopy
Images were captured with a Leica TCS SP5 Spectral Confocal Microscope, 405UV using a 363 oil immersion objective and sequential scanning with 405 diode, argon, and He/Ne laser excitation lines of 405, 488, 543, and 633 nm.
Statistics
For experiments in which more than two groups were compared, statistical significance was determined by one-way ANOVA using a 95% confidence interval and the Tukey posttest (Prism 4.0 for Macintosh). Statistical error is expressed as SEM. For experiments in which two groups were compared, a t test was used.
Results
The aim of this study is to identify proteins in EM CD4 T cells that couple TCR to TEM, focusing on signals that could potentially reorganize the cytoskeleton to form the novel TEPs we have observed during this process. We are particularly interested in signaling pathways that distinguish TCR-driven TEM from chemokine-driven TEM. To simultaneously analyze chemokine-and TCR-driven TEM, both of which are shear-stress dependent, we use TNF-treated CIITA-transduced HDMEC monolayers overlaid with superantigen TSST-1, as previously described (10, 12) , and analyze the morphology and location of isolated human peripheral blood EM CD4 T cells allowed to interact with the EC monolayer in a flow chamber apparatus that applies venular levels of shear stress. In this system, those EM CD4 T cells that express a TCR con-FIGURE 1. T cell ZAP-70 activity is required for both chemokine-driven and TCR-driven TEM. (A) TEM assays of EM CD4 T cells treated with 0, 10, 30 and 100 mg/ml piceatannol (pic) for 30 min or 0 and 40 mM Syk Inhibitor II for 60 min. Graphs show percent TEM of cells lacking the Vb2TCR (VB2 2 , which do not interact with TSST-1 and transmigrate in response to chemokines on the EC; chemokine-driven TEM) at 15-min flow (pic) or 50-min flow (Syk Inhib. II) and percent TEM of cells expressing Vb2TCR (VB2 + , those that interact with TSST-1 presented by the EC; TCR-driven TEM) after 50-min flow. Graphs display combined data from two separate experiments (pic) or one representative experiment of two (Syk inhib. II). *p , 0.001, **p , 0.0001. (B) Samples from TEM experiments were stained for Vb2TCR, NFAT, and nuclei (DAPI). Shown are samples from T cells treated with 30 and 100 mg/ml pic. Arrows point to NFAT staining in Vb2TCR + T cells. Note that NFAT is translocated to the nucleus in the Vb2TCR + T cell at 30 mg/ml pic but is excluded from the nucleus in all Vb2TCR 2 cells as well as the Vb2TCR + cell at 100 mg/ml pic. Original magnification 3300. (Fig.  1A) . To assess specificity, we stained the samples for NFAT, because TCR-mediated activation of ZAP-70 leads to activation of NFAT, detectable by immunofluorescence as translocation of this transcription factor from the cytosol to the nucleus. The effects of ZAP-70 inhibitors on TEM were observed at concentrations that corresponded with the inhibition of NFAT translocation to the nucleus in Vb2TCR + cells (Fig. 1B; data not shown), consistent with the interpretation that the effect of the inhibitors on TEM was due to the inhibition of ZAP-70.
In addition to its well-established role in TCR signaling, previous studies have reported that ZAP-70 is also involved in chemokine receptor responses (21) (22) (23) (24) . We directly assessed ZAP-70 activation by immunofluorescence microscopy using an Ab to a phosphorylated form of the enzyme. By this approach, we observed that all EM CD4 T cells bound to the ECs activate ZAP-70 but that there are marked differences in the extent and localization of ZAP-70 activation in the EM CD4 T cells depending on whether they encounter Ag presented by the EC under flow. Within a few minutes of contacting the EC surface, the cells unable to recognize TSST-1 (the Vb2TCR 2 cells) adopt the wellcharacterized polarized morphology associated with flattened crawling T cells, whereas the Vb2TCR + cells appear circular and rounded-up. Activated ZAP-70 is abundant in the Vb2TCR + cells compared with the Vb2TCR 2 cells and persists throughout the time course used in these studies (up to 50 min; Fig. 2 ; data not shown) and is located uniformly around the plasma membrane, including the TEPs, with no obvious preference for one site or another. LAT, a target of ZAP-70 kinase activity in the TCR signaling pathway, is also abundantly phosphorylated in the Vb2TCR + cells compared with the Vb2TCR 2 cells but appears to be more intense at the T cell-EC interface and similarly distributed in the TEPs (Fig. 3) . ZAP-70 has been reported to constitutively associate with LFA-1 and become activated upon LFA-1 binding to ICAM-1 (25), whereas focal dots of high-affinity LFA-1-ICAM-1 have been described in primary T cells crawling along EC under flow, although these focal dots seemed to be devoid of phosphotyrosine (7) . In EM CD4 T cells under flow, activated ZAP-70 in the cells responding to chemokine appears to colocalize with activated LFA-1 in some, but not all, areas of the cells undergoing chemokinedriven TEM, whereas activated LFA-1 broadly colocalized with phospho-ZAP-70 everywhere in the Vb2TCR + cells (Fig. 4) . In T cells, LFA-1 is activated by inside-out signals originating from chemokine receptors or the TCR. Binding of activated LFA-1 to ICAM-1 not only serves to attach the T cell to the EC but may also provide signals as well, so-called outside-in signaling. Talin and kindlin-3 control the activation and function of LFA-1 in T cells (16, 26, 27) . Talin does not appear to be localized to any particular area in either Vb2TCR + or Vb2TCR 2 cells (Fig. 5) . Staining for kindlin-3 was not successful (T.D. Manes, unpublished observations) but staining for the scaffolding protein RACK1, which forms a ternary complex with kindlin-3 and LFA-1 (17), showed an exclusion from zones underneath the nucleus in Vb2TCR + cells, whereas some dots were apparent on the ventral surface underneath the nucleus of the Vb2TCR 2 cells as well as at the leading edge and especially at the ventral surface of the uropod (Fig. 5) . In response to TCR signaling, ZAP-70 activates Vav once it is recruited to the phosphorylated LAT signalosome. T cells treated with the Vav inhibitor 6-thio-GTP reduced TCR-driven but not chemokine-driven TEM (Fig. 6A) . To support these findings and because primary resting EM CD4 T cells are not amenable to genetic manipulations such as knockdown by small interfering RNA or overexpression of proteins from genes introduced by transfection or viral transduction (T.D. Manes, unpublished observations), we adopted protein transduction of recombinant DN proteins as an alternative approach to examine cellular signaling. By using recombinant proteins fused to both a protein transduction domain (Hph-1), shown to be effective for introducing functional protein into primary T cells (28, 29) , and to EGFP as a marker, we introduced similar levels of Vav DN (20, 30) or Hph-1 fused directly to EGFP as a control into EM CD4 T cells (Fig. 6B ) and examined the transduced T cells in TEM assays. Vav DN reduced TCR-driven but not chemokine-driven TEM (Fig. 6C ).
Vav has been described to act primarily as a GEF for the Rhofamily GTPase Rac but may also act on Cdc42, another Rho-family GTPase (31) . Using the protein transduction approach described above for Vav, Rac1 and Cdc42 wt and DN proteins were transduced into EM CD4 + T cells (Fig. 7A) , and their effects were tested in TEM assays. Cdc42 DN impaired chemokine-driven TEM but had no effect on TCR-driven TEM (Fig. 7B) . Conversely, + T cell at 30 min flow with a TEP that is underneath the EC monolayer (top panels), the cell body near the apical surface of the EC (middle panels) and further above the EC interface (bottom panels). Numbers indicate micrometers above the TEP. Original magnification 3600. Rac DN had no effect on chemokine-driven TEM but reduced TCR-driven TEM (Fig. 7B) . wt versions of Rac and Cdc42 had no effect on either process compared with nontransduced cells. Treatment of EM CD4 T cells with EHop-016 reduced TCRdriven TEM at 1 mM and chemokine-driven TEM at 4 mM, consistent with the IC 50 of this inhibitor for Rac and Cdc42, respectively ( Fig. 7C) (32) .
The organization of the cytoskeleton in nonmuscle cells may be controlled either by regulating actin filament assembly or disassembly or by regulating the enzymatic activity of myosin. Myosin IIA is the only myosin II isoform in T lymphocytes (33) . To investigate myosin IIA function in TEM of EM CD4 T cells under flow, we treated the T cells with blebbistatin, a myosin IIA-selective inhibitor, and tested them in the flow assay. Surprisingly, chemokine-driven TEM was not affected, but TCR-driven TEM was blocked by blebbistatin and was accompanied by an increase in the number of TEPs (Fig. 8A) , many of which became quite extensive (Fig. 8B, 8C) . Blebbistatin had no effect on ZAP-70 activation in Vb2TCR + EM CD4 T cells detectable within the first few minutes and all time points thereafter (up to 50 min; Supplemental Fig. 1) . Similarly, treatment of T cells with myosin L chain kinase inhibitor ML-7 had no effect on chemokine-driven TEM but reduced TCR-driven TEM while augmenting the number of TEPs (Fig. 8D) . These data suggest that the primary role of myosin in TCR-driven TEM is to allow the cell body to follow the TEP across the EC monolayer rather than contribute to upstream signaling.
Discussion
In this report, we provide evidence that TCR-driven TEM of EM CD4 T cells is controlled by Vav, Rac, and myosin IIA, each of which is dispensable for chemokine-driven TEM. This process is initiated by ZAP-70, but this kinase appears to affect chemokine-driven TEM as well. This is in agreement with previous studies reporting that ZAP-70 is involved in chemokine receptor responses (21) (22) (23) (24) and explains why we did not see a reversal of the TCR "stop" signal, as was seen with lck inhibitors (9) . Because ZAP-70 is constitutively associated with LFA-1 and becomes activated upon LFA-1 binding to ICAM-1 (25) , it may be postulated that activated ZAP-70 may colocalize to the sites of high-affinity LFA-1-ICAM-1 described in primary T cells crawling along EC under flow, even though staining with anti-phosphotyrosine Abs indicated that the focal dots did not contain phosphotyrosine (7) . Staining of EM CD4 T cells undergoing chemokine-driven TEM for activated ZAP-70, although very weak, and activated LFA-1 indicated that there may be some colocalization of these two molecules. Because ZAP-70 levels are elevated in memory compared with naive T cells (34) , this may explain why it was not detected previously. In contrast, activation of ZAP-70 in TCR-stimulated T cells is much more robust and distributed throughout the entire plasma membrane as revealed by immunofluorescence microscopy. Furthermore, a substrate of ZAP-70, LAT, is negligibly phosphorylated in T cells undergoing chemokine-driven TEM as compared with TCR-driven TEM. The differences in the site and extent of ZAP-70 activation likely explain how the same enzyme can activate distinct downstream signaling pathways. Indeed, the confocal analysis of all molecules examined in this study, including activated LFA-1, talin, and RACK1, support the assertion that a major difference between chemokine-driven and TCR-driven TEM is the early change in cell shape and polarity, a process controlled by polarity proteins, which are required for conformational changes triggered by TCR signaling (35) . It should be noted that, although essentially all of the TCR-activated cells have activated ZAP-70 and adopt a different morphology as compared with the chemokine-driven transmigrating cells, not all of these will form TEPs and transmigrate in the time course analyzed, indicating that although the "stop" signals are shared between all EM CD4 T cells, there may be some other signals that are necessary for TCR-driven TEM besides those from the TCR or that our analysis did not extend long enough. The ability to follow TCR-driven TEM for longer time points is hampered by the downregulation of the TCR on the TSST-1-interacting T cells after ∼90 min of flow, and hence the inability to detect and analyze those cells with the anti-Vb2TCR Ab at time points after that (T.D. Manes, unpublished observations). By analyzing cells by immunofluorescence microscopy at the 30-min time point, we were able to examine cells in the later stages of TCR-driven TEM; many had TEPs, and some even showed nuclei in transit through the monolayer. It appears that phospho-ZAP-70 and phospho-LAT (and SLP-76; data not shown) are located not just at the T cell-EC interface at early time points, but also in the TEPs, suggesting that TEPs are a site of active signaling. TEPs also contain activated LFA-1 and talin, as well as RACK1, a molecule that associates with both kindlin-3 and LFA-1 and may regulate LFA-1 affinity and outside-in signaling (17) . Of all these proteins, only RACK1 displayed any sort of selective distribution, being excluded from zones underneath nuclei. The significance of this particular localization is unclear.
In TCR signaling, src-family kinase-phosphorylated ITAM motifs of the CD3 z chain at the plasma membrane recruit and activate ZAP-70, which in turn phosphorylates LAT and SLP-76, leading to recruitment and activation of Vav, as well as other downstream mediators. We expected that the activation of Vav would provide a direct link between TCR signaling and the reorganization of the cytoskeleton that is required for TCR-driven TEM, and reduction of TCR-driven TEM of T cells treated with a pharmacological inhibitor of Vav, 6-thio-GTP, supports that hypothesis. However, because pharmacological inhibitors have off-target effects, and another pharmacological inhibitor of Vav is not available, we sought to support these findings using transduction of a recombinat DN protein. This approach was required because genetic manipulation of EM CD4 T cells, such as overexpression from a transfected or transduced vector or knockdown by small interfering RNA, requires time to exert its effect and prolonged culture of primary human peripheral blood T cells changes the characteristics of the cells such that they are no longer truly resting EM T cells. Significantly, EM CD4 T cells lose expression of receptors necessary for TCR-driven TEM after a few days in culture (T.D. Manes, unpublished observations). Therefore, to investigate Vav function in EM CD4 T cells, we exploited a technique used successfully by others to modify intracellular events in primary T cells, namely introducing functional proteins via fusion to a protein transduction domain peptide called Hph (28) . Hph-fusion proteins enter the cell within a 1-h incubation and are functional after overnight incubation or perhaps sooner. Although the levels of transduction for all proteins used in these studies were concentration dependent, the maximum amount of any given protein that could be transduced into an EM T cell varied with the identity of the protein domains fused to the Hph transduction domain. Unexpectedly, lower levels of control Hph-EGFP could be introduced into the cell than the other proteins used in this study, all of which are fused to EGFP. Therefore it was fortunate that relatively low levels of Hph-EGFP-Vav DN (similar to levels of control EGFP) were able to produce an effect because we could not control for off-target or nonspecific effects following higher levels of transduction. Consistent with the observations reported in this study for human EM CD4 T cells, genetic knockout of Vav in mice inhibits Ag-specific but not chemokinedriven recruitment of primed T cells in peripheral tissues (36) .
Vav is the primary Rac GEF in TCR signaling, and indeed, Rac appears to control TCR-driven TEM. Pharmacological inhibition of Cdc42 has been reported to inhibit chemokine-driven TEM of primary human CD4 cells under flow (7), and our results using cells transduced with a Cdc42 DN protein and treated with another pharmacological inhibitor support those findings. It is perhaps surprising that Rac DN did not inhibit chemokine-driven TEM or adhesion to the EC, as mouse Rac1 and Rac2 double-knockout T cells are defective in secondary lymph node homing in vivo as well as adhesion to and TEM across CCL21-overlaid EC in vitro under flow (37) . Furthermore, transduction of total primary human peripheral blood T cell populations with Rac DN protein inhibited binding to ICAM-1 in response to CXCL12 in vitro as well as arrest on mouse high endothelial venules in vivo (38) . However, it should be noted that the T cells used in those studies are either all (in the mouse model) or substantially (total T cells from human blood) naive, responding to homeostatic chemokines, whereas our studies used purified EM human T cells (typically ,10% of total T cells) responding to inflammatory chemokines. In other words, different chemokine receptors may activate distinct signaling pathways. Indeed, Rac1 has been shown to associate with and control CXCR4, the receptor for CXCL12, but not other related chemokine receptors (39) . Consistent with these findings, two Racspecific GEFs, namely DOCK2 and Tiam, control homeostatic recirculation through lymphoid organs (40) (41) (42) . Thus, although Rac may play a role in homeostatic recirculation of naive T cells, it may not be involved in the response of EM T cells to inflammatory chemokines.
Although inhibition of Vav and Rac both reduced TCR-driven TEM of human EM CD4 T cells, they did not significantly affect TEP formation. This was a surprise because we had hypothesized that TEPs were related to lamellipodia, a cellular protrusion that is controlled by Rac. Our new findings suggest that TEPs are a unique cellular structure and further investigation will be required to understand their formation.
In our study, we identified a role for myosin IIA in allowing the T cell body to follow TEP formation and lead to TEM. Myosin IIA activity has also been reported to be necessary for maturation of microclusters and sustained TCR signaling at the immunological synapse, affecting ZAP-70 activation by src kinases in T cells interacting with professional APCs or planar bilayers in shearfree conditions (43) . In our system (i.e., EM CD4 T cells interacting with superantigen presented by EC under conditions of flow), blebbistatin did not affect ZAP-70 activation. Rather, myosin IIA appears to be acting downstream of ZAP-70, because TEP formation is prevented by piceatannol but not by blebbistatin. TEPs are dynamic, undergoing both extension and retraction. The concomitant increase in TEPs (both in number and size) and decrease in TEM in samples treated with blebbistatin suggests that myosin IIA may be controlling two events: the retraction of the TEP as it probes the subendothelial surface and the release of the nucleus into the TEP to complete TEM. Both processes may involve de-adhesion of the T cell or its TEP, and myosin IIA has been associated with de-adhesion of the T cell uropod in a previous study (44) . Interestingly, in our previous work (10), we had observed that fractalkine signals were needed for completion of TCR-driven TEM but not for TEP formation. It is therefore possible that myosin IIA activation, which appears to play a similar role, may be downstream of fractalkine signaling.
The unique intracellular signaling pathway that controls TCRdriven TEM as opposed to chemokine-driven TEM may have significant therapeutic implications. EM CD4 T cells are present in the circulation of every normal adult and produce inflammatory cytokines (TNF and IFN-g) rapidly after TCR stimulation (2). They are perfectly positioned, then, to act as "pioneers" in an inflammatory response, where a small number of Ag-specific EM T cells are activated and recruited by Ag-presenting EC and, via production of TNF and IFN-g, initiate a cascade of Ag-independent recruitment of other leukocytes (8, 45) . In this scenario, interfering with the recruitment of the pioneers is an attractive approach to prevent the onset of an unwanted inflammatory response such as allograft rejection. Evidence in support of this concept has been provided by studies of the effects of azathioprine, a widely used immunosuppressant whose mode of action has been elucidated relatively recently; azathioprine is metabolized to 6-Thio-GTP and inhibits Vav GEF-mediated activation of Rac in T cells (46) . An interpretation of these findings has been that azathioprine inhibits activation of naive T cells. An alternative, but not mutually exclusive, possibility is that azathioprine may inhibit TCR-driven recruitment of EM CD4 T cells.
